ShunzymeX is a precision microbial purification platform that streamlines downstream processing for complex biologics. By using an engineered, scarless protease, the technology enables the use of standard affinity resins to isolate proteins, followed by clean tag removal. This approach significantly reduces development timelines, improves yields, and simplifies the path to GMP-compliant manufacturing for pharmaceuticals and advanced therapies.
ShunzymeX is a precision purification technology designed to streamline the downstream processing of complex biological medicines. Developed through a strategic partnership between the University of Edinburgh and FUJIFILM Biotechnologies, this platform addresses significant bottlenecks in microbial protein production. By simplifying the purification workflow, the technology accelerates process development and facilitates a faster, more reliable transition from laboratory research to Good Manufacturing Practice (GMP) production. It provides a robust, scalable solution that improves yields and purity for a variety of microbial expression systems.
The platform utilizes a proprietary, engineered protease that enables a scarless purification process. Key features include:
The technology is currently at TRL 9. It has been successfully developed, validated, and launched as a commercial platform by FUJIFILM Biotechnologies, a leading global contract development and manufacturing organization (CDMO), with ongoing industry deployment for biologics manufacturing.
The University of Edinburgh is a comprehensive, research‑intensive public university in Scotland’s capital. Industry engages through co‑located facilities and innovation hubs that bring companies into the university ecosystem, including the Bayes Centre for data and AI and the Usher Institute at the Edinburgh BioQuarter. Integration with NHS Lothian at BioQuarter places hospital care, clinics and university research on a single site to speed clinical studies and translation. Research is supported by competitive UK government funding via UKRI and Innovate UK, alongside major charitable funders such as Wellcome. A dedicated technology transfer company, Edinburgh Innovations, streamlines access to expertise, IP management, licensing and venture creation.